Jake A. Kleinmahon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jake A. Kleinmahon has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
S. Bora
Mothers, Babies And Women’s Health, Mater Research Institute, Faculty of Medicine, The University of Queensland, South Brisbane, Australia
2 shared publicationsT. Chin
Mothers, Babies And Women’s Health, Mater Research Institute, Faculty of Medicine, The University of Queensland, South Brisbane, Australia
2 shared publicationsA. Barnes
Children's Mercy Hospital, Kansas City, MO
1 shared publication- Alessandro Mussa
Department of Public Health and Pediatric Sciences University of Torino Torino Italy
1 shared publication - Alfred Asante‐Korang
Division of Cardiology, Department of Pediatrics Johns Hopkins All Children's Heart Institute Saint Petersburg Florida USA
1 shared publication Andrew J. Savage
Division of Pediatric Cardiology, Medical University of South Carolina, Charleston, South Carolina
1 shared publication
Latest Publications
- 11 March 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (3) , e70295
Addressing Healthcare Disparities in Pediatric Thoracic Transplantation: A Blueprint for Change
Outcomes in pediatric thoracic transplantation have significantly improved, yet stark inequities persist. Disparities arise from biases in the healthcare system toward racial, ethnic, or religious groups as well as LGBTQ+ patients and families. Furthermore, geographic and socioeconomic factors and other social determinants of health also play an important role in outcomes. While the impact of these disparities on pediatric transplant recipients has been previously reported, a comprehensive approach to address these root causes is lacking. This article reviews the existing literature on the origins and manifestations of healthcare disparities in pediatric thoracic transplantation. Building upon this analysis, we then propose a blueprint for change, outlining actionable strategies to address the identified causes of inequity and, ultimately, improve outcomes for all pediatric thoracic transplant patients.
- 11 March 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (3) , e70295
Addressing Healthcare Disparities in Pediatric Thoracic Transplantation: A Blueprint for Change
Outcomes in pediatric thoracic transplantation have significantly improved, yet stark inequities persist. Disparities arise from biases in the healthcare system toward racial, ethnic, or religious groups as well as LGBTQ+ patients and families. Furthermore, geographic and socioeconomic factors and other social determinants of health also play an important role in outcomes. While the impact of these disparities on pediatric transplant recipients has been previously reported, a comprehensive approach to address these root causes is lacking. This article reviews the existing literature on the origins and manifestations of healthcare disparities in pediatric thoracic transplantation. Building upon this analysis, we then propose a blueprint for change, outlining actionable strategies to address the identified causes of inequity and, ultimately, improve outcomes for all pediatric thoracic transplant patients.
- 13 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1773-1780
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction
- 13 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1773-1780
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S518-S519
Outcomes of Intracorporeal Continuous, Paracorporeal Continuous, and Paracorporeal Pulsatile Ventricular Assist Devices in Pediatric Patients 10-30 kg
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S518-S519
Outcomes of Intracorporeal Continuous, Paracorporeal Continuous, and Paracorporeal Pulsatile Ventricular Assist Devices in Pediatric Patients 10-30 kg
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 02) , S67-S103
AKT/mTOR and MAPK Inhibition Improves Childhood RASopathic Cardiomyopathy
Background: RASopathies are a spectrum of pleomorphic syndromic disorders and caused by germline mutations in the RAS/mitogen-activated protein kinase (MAPK) pathway. They cause progressive RASopathy-associated cardiomyopathy (RAS-CM) for which no preventive or curative therapies exist. Young infants presenting with heart failure suffer from high mortality. RAS-CM presenting later in life is morbid with increased risk for sudden cardiac death or cardiac transplantation. Animal studies and limited case reports have suggested that small molecule inhibitors of target of rapamycin (mTOR) or mitogen-activated protein kinase kinase (MEK), pathways activated in certain RASopathies, are beneficial. The aim of this study is to report on 25 patients from Europe and North America with progressive and/or life-threatening RAS-CM in whom we initiated off-label or compassionate inhibition of mTOR or MEK after exhaustion of standard therapies. Method: This study was done by retrospective data collection. Results: Over a follow-up period of 296 patient-months (median, 5.5 months; range, 1.5–50), we observed increased transplant-free survival in critically ill patients <6 months of age treated with mTORi and/or MEKi as compared with that from natural history studies (75 vs. 39%, p = 0.031). Freedom from surgical intervention was 52% (11 of 21 patients in whom surgical outflow tract resection was indicated), and clinically meaningful improvement (greater than 20% from baseline) in 50% or more of preselected cardiac outcome variables occurred in 18 of 25 patients (72%) undergoing mTORi and/or MEKi treatment. No life-threatening adverse events related to mTORi or MEKi occurred. Conclusion: These data suggest that selected RASopathy patients may benefit from mechanism-informed therapeutics guided by the biological understanding of cardiac pathology in this disease spectrum. Publication Date: 12 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 02) , S67-S103
AKT/mTOR and MAPK Inhibition Improves Childhood RASopathic Cardiomyopathy
Background: RASopathies are a spectrum of pleomorphic syndromic disorders and caused by germline mutations in the RAS/mitogen-activated protein kinase (MAPK) pathway. They cause progressive RASopathy-associated cardiomyopathy (RAS-CM) for which no preventive or curative therapies exist. Young infants presenting with heart failure suffer from high mortality. RAS-CM presenting later in life is morbid with increased risk for sudden cardiac death or cardiac transplantation. Animal studies and limited case reports have suggested that small molecule inhibitors of target of rapamycin (mTOR) or mitogen-activated protein kinase kinase (MEK), pathways activated in certain RASopathies, are beneficial. The aim of this study is to report on 25 patients from Europe and North America with progressive and/or life-threatening RAS-CM in whom we initiated off-label or compassionate inhibition of mTOR or MEK after exhaustion of standard therapies. Method: This study was done by retrospective data collection. Results: Over a follow-up period of 296 patient-months (median, 5.5 months; range, 1.5–50), we observed increased transplant-free survival in critically ill patients <6 months of age treated with mTORi and/or MEKi as compared with that from natural history studies (75 vs. 39%, p = 0.031). Freedom from surgical intervention was 52% (11 of 21 patients in whom surgical outflow tract resection was indicated), and clinically meaningful improvement (greater than 20% from baseline) in 50% or more of preselected cardiac outcome variables occurred in 18 of 25 patients (72%) undergoing mTORi and/or MEKi treatment. No life-threatening adverse events related to mTORi or MEKi occurred. Conclusion: These data suggest that selected RASopathy patients may benefit from mechanism-informed therapeutics guided by the biological understanding of cardiac pathology in this disease spectrum. Publication Date: 12 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 8 November 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29, S240
452 Brain Injuries in Children With Congenital Heart Disease: A Systematic Review and Meta-Analysis
- 8 November 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29, S240
Open Access452 Brain Injuries in Children With Congenital Heart Disease: A Systematic Review and Meta-Analysis
- Open Access
- 8 November 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29, S342
679 Psychological Outcomes of Parents of Children With Congenital Heart Disease: A Systematic Review and Meta-Analysis
- 8 November 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29, S342
Open Access679 Psychological Outcomes of Parents of Children With Congenital Heart Disease: A Systematic Review and Meta-Analysis
- 1 August 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 146 (2)
Acute Fulminant Myocarditis in a Pediatric Patient With COVID-19 Infection
The majority of patients with coronavirus disease 2019 (COVID-19) display pulmonary disease; however, a significant portion of patients have cardiac injury as well, with a high incidence of myocarditis documented in the adult population. Pediatric disease from COVID-19 has been relatively rare, and no cases of virus-related cardiac disease have been published. We present a case of an adolescent girl with fulminant myocarditis with complete heart block, elevated troponin I levels, and severely depressed systolic function in the setting of COVID-19 infection.
- 1 August 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 146 (2)
Acute Fulminant Myocarditis in a Pediatric Patient With COVID-19 Infection
The majority of patients with coronavirus disease 2019 (COVID-19) display pulmonary disease; however, a significant portion of patients have cardiac injury as well, with a high incidence of myocarditis documented in the adult population. Pediatric disease from COVID-19 has been relatively rare, and no cases of virus-related cardiac disease have been published. We present a case of an adolescent girl with fulminant myocarditis with complete heart block, elevated troponin I levels, and severely depressed systolic function in the setting of COVID-19 infection.
- 1 March 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (3) , 277-284
Cardiac allograft vasculopathy and graft failure in pediatric heart transplant recipients after rejection with severe hemodynamic compromise
- 1 March 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (3) , 277-284
Cardiac allograft vasculopathy and graft failure in pediatric heart transplant recipients after rejection with severe hemodynamic compromise
- 21 September 2017
- Published by Wiley in Pediatric Transplantation
- Vol. 21 (8)
Hearts transplanted after circulatory death in children: Analysis of the International Society for Heart and Lung Transplantation registry
We aimed to describe worldwide DCD HT experience in children using the International Society for Heart and Lung Transplantation Registry. The Registry was queried for primary HT performed in children (2005‐2014). Kaplan‐Meier analysis was used to assess survival for recipients grouped by DCD or DBD hearts. Recipient characteristics were compared between DCD and DBD and between survivors and non‐survivors of DCD HT. Among 3877 pediatric HT performed, 21 (0.5%) were DCD. DCD 1‐year survival was 61% vs 91% DBD, P < .01. DCD recipients were more often supported by ECMO pre‐HT (24% vs 6%, P < .001) and more often receiving inhaled nitric oxide (10% vs 0.6%, P < .001) compared to DBD. Older DCD recipients had significantly lower 1‐year survival of 57% vs 93% for DBD, P < .01. Survival for infant DCD recipients was not statistically different to DBD recipients (survival 62% at 1 year and 62% at 5 years for DCD vs 85% at 1 year and 77% at 5 years for DBD, P = .15). Recipients of DCD HT who died were more often supported by ECMO pre‐HT (56% non‐survivors vs 0% survivors, P = .004) and receiving mechanical ventilation (44% vs 0%, P = .012). DCD HT is uncommon in children. DCD‐independent factors in recipients may have contributed to worse survival as DCD recipients who died were more often supported by ECMO and mechanical ventilation. More research is needed to identify donor factors and recipient factors that contribute to mortality after DCD HT.
- 21 September 2017
- Published by Wiley in Pediatric Transplantation
- Vol. 21 (8)
Hearts transplanted after circulatory death in children: Analysis of the International Society for Heart and Lung Transplantation registry
We aimed to describe worldwide DCD HT experience in children using the International Society for Heart and Lung Transplantation Registry. The Registry was queried for primary HT performed in children (2005‐2014). Kaplan‐Meier analysis was used to assess survival for recipients grouped by DCD or DBD hearts. Recipient characteristics were compared between DCD and DBD and between survivors and non‐survivors of DCD HT. Among 3877 pediatric HT performed, 21 (0.5%) were DCD. DCD 1‐year survival was 61% vs 91% DBD, P < .01. DCD recipients were more often supported by ECMO pre‐HT (24% vs 6%, P < .001) and more often receiving inhaled nitric oxide (10% vs 0.6%, P < .001) compared to DBD. Older DCD recipients had significantly lower 1‐year survival of 57% vs 93% for DBD, P < .01. Survival for infant DCD recipients was not statistically different to DBD recipients (survival 62% at 1 year and 62% at 5 years for DCD vs 85% at 1 year and 77% at 5 years for DBD, P = .15). Recipients of DCD HT who died were more often supported by ECMO pre‐HT (56% non‐survivors vs 0% survivors, P = .004) and receiving mechanical ventilation (44% vs 0%, P = .012). DCD HT is uncommon in children. DCD‐independent factors in recipients may have contributed to worse survival as DCD recipients who died were more often supported by ECMO and mechanical ventilation. More research is needed to identify donor factors and recipient factors that contribute to mortality after DCD HT.
- Open Access
- 7 June 2017
- Published by IntechOpen
Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients
Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients | InTechOpen, Published on: 2017-06-07. Authors: Jake A. Kleinmahon and Bruce F. Landeck, II
- 7 June 2017
- Published by IntechOpen
Open AccessEvaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients
Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients | InTechOpen, Published on: 2017-06-07. Authors: Jake A. Kleinmahon and Bruce F. Landeck, II